Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
670 studies found for:    Epoetin alfa OR Epogen, Procrit[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Active, not recruiting Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Conditions: Anemia;   Chronic Kidney Disease (CKD)
Interventions: Drug: HX575 epoetin alfa;   Drug: US-licensed epoetin alfa
2 Terminated
Has Results
Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa
Condition: Subarachnoid Hemorrhage
Interventions: Drug: Epoetin alfa;   Drug: Saline
3 Completed Comparison Among Erythropoietin Stimulating Agents
Condition: Anemia of End Stage Renal Disease
Interventions: Drug: Epoetin alpha or beta (Epoetin group);   Drug: Darbepoetin alfa;   Drug: Methoxy polyethylene glycol-epoetin beta
4 Withdrawn Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia
Condition: Anemia
Intervention: Drug: Epoetin Alfa plus Iron
5 Completed
Has Results
An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease
Condition: Anemia
Interventions: Drug: Epoetin alfa 3 times weekly /once weekly;   Drug: Epoetin alfa once weekly;   Drug: Epoetin alfa once every two weeks
6 Completed HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
Condition: Chronic Kidney Disease
Intervention: Drug: HX575 epoetin alfa (Sandoz)
7 Active, not recruiting Efficacy Study of Epoetin Alfa in Friedreich Ataxia
Condition: Friedreich Ataxia
Interventions: Drug: Epoetin alfa;   Drug: Placebo
8 Active, not recruiting
Has Results
Erythropoetin Neuroprotection for Neonatal Cardiac Surgery
Conditions: Congenital Heart Disease;   Hypoplastic Left Heart Syndrome;   Transposition of the Great Arteries;   Aortic Arch Hypoplasia or Interruption
Interventions: Drug: Erythropoetin;   Drug: Normal saline
9 Terminated
Has Results
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
Condition: Anemia
Interventions: Drug: Peginesatide;   Drug: Epoetin alfa
10 Completed
Has Results
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Leukemia
Intervention: Drug: Procrit
11 Terminated
Has Results
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Conditions: Neoplasms;   Anemia;   Cancer
Interventions: Drug: epoetin alfa;   Drug: darbepoetin alfa
12 Terminated
Has Results
The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery
Condition: Hemostasis, Surgical
Interventions: Drug: Epoetin alfa;   Drug: Standard of Care
13 Completed
Has Results
A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.
Conditions: Renal Failure , Chronic;   Anemia
Interventions: Drug: Epoetin Alfa;   Other: Standard of care
14 Completed Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia
Condition: Friedreich's Ataxia
Intervention: Drug: Epoetin alfa
15 Completed
Has Results
Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy
Condition: Cerebral Palsy
Interventions: Biological: Umbilical Cord Blood Infusion;   Drug: Erythropoietin Injection;   Other: Active Rehabilitation;   Other: Placebo Umbilical Cord Blood;   Other: Placebo Erythropoietin
16 Completed
Has Results
Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy
Condition: Leukemia
Intervention: Drug: Procrit (epoetin alfa)
17 Withdrawn Epoetin Alfa for HIV-Associated Neuropathy Trial
Conditions: HIV Infections;   Neuropathy
Intervention: Drug: epoetin alfa
18 Completed A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa
Condition: Pure Red-cell Aplasia
Intervention: Drug: No intervention
19 Completed Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis
Condition: Nephrology
Interventions: Drug: Epoetin alfa RB;   Drug: Epoetin alfa DT
20 Completed A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Conditions: Chronic Kidney Disease;   Chronic Renal Failure
Interventions: Biological: Epoetin Hospira;   Biological: Epogen (Amgen)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years